Stephen D. Simpson, CFA

  1. Portfolio Basics For The Beginner Investor
    Mutual Funds & ETFs

    Portfolio Basics For The Beginner Investor

    By following some broad allocation guidelines, new investors can build the portfolio they want.
  2. A Nabor-ly Deal For Superior Well Services
    Stock Analysis

    A Nabor-ly Deal For Superior Well Services

    Nabors takes a large step into the services arena, and a prime buyout target goes away.
  3. Why Transocean Will Recover
    Stock Analysis

    Why Transocean Will Recover

    Transocean's stock has taken a beating since the Macondo disaster, but the quality of company should make the stock a long-term winner.
  4. Still Time To Buy Hologic
    Stock Analysis

    Still Time To Buy Hologic

    Hologic is still suffering from the economy, but more profitable days should lie ahead.
  5. Can Oshkosh Keep On Truckin'?
    Stock Analysis

    Can Oshkosh Keep On Truckin'?

    Wall Street is expecting very little out of this heavy duty truck builder; so little that outperformance could mean sizable gains for patient investors.
  6. HSBC's Earnings Mystery
    Stock Analysis

    HSBC's Earnings Mystery

    The world's third-largest bank is experiencing a slow recovery, but things are still not as good as the recent earnings report suggested.
  7. Economic Cults - Don't Drink The Kool-Aid
    Economics

    Economic Cults - Don't Drink The Kool-Aid

    Too often economists present themselves more like witch doctors and high priests. Learn to separate the valid from the voodoo.
  8. Ultra Petroleum - Low-Cost, High-Quality
    Stock Analysis

    Ultra Petroleum - Low-Cost, High-Quality

    Quality and value are usually a trade-off on Wall Street, but Ultra Petroleum seems to offer both.
  9. Santander's Footprint Pays Off
    Stock Analysis

    Santander's Footprint Pays Off

    Santander's fast-growing Latin business provides a spicy contrast to the sour state of Spain.
  10. Sanofi Has To Do Something
    Stock Analysis

    Sanofi Has To Do Something

    Sanofi is priced as though it will never grow again - that's usually a good sign of value.
  11. The Biggest Corporate Image Catastrophes
    Personal Finance

    The Biggest Corporate Image Catastrophes

    Despite spending millions of dollars on PR, some companies still manage to muddy their reputations with tone-deaf responses to trouble.
  12. Thermo Fisher Gets Cool Reception
    Stock Analysis

    Thermo Fisher Gets Cool Reception

    Wall Street did not like Thermo's guidance, but that could be an opportunity for patient investors looking for a low-beta life sciences play.
  13. Arch Capital - A Weak Market Will Take Its Toll Eventually
    Stock Analysis

    Arch Capital - A Weak Market Will Take Its Toll Eventually

    Arch Capital continues to manage a soft rate cycle, but eventually it will constrain the company's ability to grow.
  14. IlIllumina A Bright Spot In Its Industry
    Stock Analysis

    IlIllumina A Bright Spot In Its Industry

    Illumina is leading the way in sequencing, but are investors profiting as well?
  15. Recovery? Specialty Chemicals Lead The Way
    Stock Analysis

    Recovery? Specialty Chemicals Lead The Way

    Double-digit volume growth from chemical companies seems like a positive sign for the economic recovery.
  16. Weird Insurance Bets Worth Millions
    Insurance

    Weird Insurance Bets Worth Millions

    These are not the policies written by the folks in grey flannel suits.
  17. A Tale Of 3 Banks
    Stock Analysis

    A Tale Of 3 Banks

    No matter where you look, loan growth is weak, but credit quality is slowly recovering.
  18. Nucor Not In The Clear
    Stock Analysis

    Nucor Not In The Clear

    Another cautious outlook from the steel industry puts the economic recovery in question.
  19. ABB Is Better Than You Think
    Stock Analysis

    ABB Is Better Than You Think

    Sluggish performance this quarter hides the quality and cash generation capability of this Swiss conglomerate.
  20. How Cool Is Ingersoll Rand?
    Stock Analysis

    How Cool Is Ingersoll Rand?

    Might Ingersoll Rand's good news be seen as bad news for the broader market?
  21. 10 Investing Tips From Heavy Metal
    Active Trading

    10 Investing Tips From Heavy Metal

    Duelling guitars, frenetic drumming, ear-splitting vocals... and solid investment advice?
  22. Stryker Needs A Growth Resurfacing
    Stock Analysis

    Stryker Needs A Growth Resurfacing

    Stryker is a former growth darling struggling to regain its mojo, but the valuation is enticing.
  23. VMWare's Vaporous Valuation
    Stock Analysis

    VMWare's Vaporous Valuation

    The growth is great, but can any company grow enough to justify VMWare's valuation?
  24. Building a Portfolio Around Brazil's Building
    Stock Analysis

    Building a Portfolio Around Brazil's Building

    Brazil will be spending billions in preparations for the World Cup and Olympics, and most of that money will stay at home.
  25. Bank Of New York Marking Time
    Stock Analysis

    Bank Of New York Marking Time

    Custody is not an exciting business, but investors should not overlook this toll collector in financial services.
  26. Bank Of America And Citigroup - Credit Now Giveth
    Stock Analysis

    Bank Of America And Citigroup - Credit Now Giveth

    Investors need to look closely at bank earnings; not all beats are the same.
  27. Novartis On The Right Track
    Stock Analysis

    Novartis On The Right Track

    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma.
  28. Bye Bye NBTY
    Stock Analysis

    Bye Bye NBTY

    This volatile supplements company goes away, and private equity is back.
  29. Investigators Send Home Health Care To The Hospital
    Stock Analysis

    Investigators Send Home Health Care To The Hospital

    Investigations by the Senate and SEC have rattled this sector, but there is still long-term value.
  30. A New Patent Problem For Smartphone Makers
    Stock Analysis

    A New Patent Problem For Smartphone Makers

    The company that secured a major settlement from RIMM is now targeting the new giants of smartphones.
  31. Ritchie Bros Feels The Hammer
    Stock Analysis

    Ritchie Bros Feels The Hammer

    Ritchie Bros spooked the market with a mid-quarter update, but the growth strategy still makes sense.
  32. Can You Maintain Virtue In Vice Stocks?
    Economics

    Can You Maintain Virtue In Vice Stocks?

    When a company's fundamental business carries moral questions, it creates more questions and complications for investors.
  33. Why There Are Always Stocks Worth Owning
    Personal Finance

    Why There Are Always Stocks Worth Owning

    No matter how bad the market gets, the right stocks are a good buy. Find out why.
  34. Will The EPA Crack Down On
    Stock Analysis

    Will The EPA Crack Down On "Fracking"?

    The Gulf oil spill has pushed pollution concerns to the forefront, and helped to put shale gas exploration back on the EPA's agenda.
  35. Iron-Clad Swaps
    Stock Analysis

    Iron-Clad Swaps

    The iron ore market is becoming increasingly open, but at the cost of more volatility.
  36. New EPA Rules Could Stir The Air
    Stock Analysis

    New EPA Rules Could Stir The Air

    New clean air regulations will burden the utility sector, but could create opportunities for others.
  37. 5 Factors To Watch In A Housing Recovery
    Home & Auto

    5 Factors To Watch In A Housing Recovery

    What are the economic signs that will point the way to a better housing market?
  38. 7 Hot Medical Device Ideas
    Stock Analysis

    7 Hot Medical Device Ideas

    These seven med-tech stocks are blazing a growth trail through their markets.
  39. Cancer Vaccines Continue To Show Promise
    Stock Analysis

    Cancer Vaccines Continue To Show Promise

    Dendreon has put cancer vaccines back in the spotlight, but can they live up to their hype?
  40. 5 Things To Do Before Interest Rates Go Up
    Economics

    5 Things To Do Before Interest Rates Go Up

    It is inevitable that interest rates will go up, but what should investors do to prepare themselves?
  41. Playing Big Pharma With CROs
    Stock Analysis

    Playing Big Pharma With CROs

    Investors looking to play the growth in R&D spending for human drugs should consider CROs.
  42. Time For Gilead To Open Its Wallet
    Stock Analysis

    Time For Gilead To Open Its Wallet

    Gilead has carved out an exceptionally valuable niche, but should the company do more?
  43. Is Another Wave Of Biotech M&A On The Way?
    Stock Analysis

    Is Another Wave Of Biotech M&A On The Way?

    If biotech companies are buying each other, should investors get in on the action?
  44. General Mills Treads Water
    Stock Analysis

    General Mills Treads Water

    General Mills is seeing good volume, but that's not enough to make it a great stock.
  45. The Next McDonald's
    Stock Analysis

    The Next McDonald's

    Should investors take a nibble on any of the chains looking to unseat McDonald's?
  46. What Ails Amgen?
    Stock Analysis

    What Ails Amgen?

    Amgen is being treated like just another Big Pharma laggard, but analysis suggests there is more growth potential here.
  47. Is Cheap Chinese Labor Over?
    Stock Analysis

    Is Cheap Chinese Labor Over?

    "Cheap China" is increasingly becoming an anachronism. What does this mean for companies that depend on low wages?
  48. Profits In For-Profit Education
    Stock Analysis

    Profits In For-Profit Education

    For-profit education is here to stay, so which names should investors study up on?
  49. Muni-phobia
    Stock Analysis

    Muni-phobia

    There is a growing drumbeat that municipal bonds may be the next domino to fall in this recession.
  50. There Is Life After Death, At Least In Biotech
    Stock Analysis

    There Is Life After Death, At Least In Biotech

    Clinical failure is not the end of the story for all biotechs. How do some survive while others disappear?